$SAVA What is the market not pricing in at current levels? ADAS-Cog 11 stability (market is expecting a decline) ADAS-Cog11 improvement from 6 to 9 months, which no drug has ever accomplished previously Small molecules that target misfolded proteins have not been proven to have a waning effect 6-month biomarker data that is consistent with or better than the 28 day biomarker data 12-month cognitive data is scheduled to be released in September/October with 12-month biomarker data to follow shortly thereafter SavaDx results that demonstrate that it was effective in a controlled study of 64 patients with Alzheimer's disease Breakthrough designation (BTD) will be awarded in the near future